Wednesday, June 18, 2025 6/18/2025

Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic

Award Number: R43HL142315
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/17/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2021

Group Awards By:

View Award Description

Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic - 7. PROJECT SUMMARY Millions of Americans suffer from sleep disturbances among which insomnia is the most common. Insomnia is often poorly treated with current pharmacotherapies and we propose to develop a new sleep-promoting therapeutic based on selective and direct activation of the G protein-gated inward rectifier K+ channels (GIRK). GIRK channels in the brain (predominantly GIRK1/2) play a key role in controlling neuronal excitability. Activation of the GIRK channels by neurotransmitters and neuropeptides, such as GABA and galanin, promote sleep. The link between GIRK function and animal NREM sleep was based on both preclinical and clinical evidence that shows GIRK activation by GABAB agonists, e.g., baclofen and ¿-hydroxybutyric acid (GHB), preferentially promote non-rapid eye movement (NREM) sleep, leading to enhanced maintenance of sleep. In our collaborative project led by Dr. Weaver, we discovered the GIRK channel biologic probe ML297, which selectively activates recombinant human GIRK channels with a half-maximal effective concentration (EC50) of ~160 nM for neuronal GIRK1/2 with a ~4-fold selectivity over cardiac GIRK1/4 channels. Recently, we eliminated the concern of ML297 on cardiac safety using the cardiac ion channels panel consisting of hERG, hCav1.2 and hNav1.5 channels (IC50 =52, 22 and >30µM, respectively). ML297 had little effects on spontaneous action potential firing in hiPSC–derived cardiomyocytes upto 10µM. Pharmacokinetic (PK) studies indicated that ML297 had acceptable brain penetration. Pharmacodynamic (PD) studies confirmed that ML297 can activate native neuronal GIRK channels in hypocretin/orexin neurons and hippocampal neurons. Furthermore ML297 (30–60 mg/kg, i.p.) inhibited spontaneous activity and prolonged inactive/sleep state in mice using our validated noninvasive wake/sleep monitoring system– SmartCageTM. A study employing electroencephalogram and electromyogram (EEG/EMG) recordings revealed that ML297 significantly enhanced NREM sleep in mice in a dose-dependent manner. We now propose to use ML297 as a starting point to develop a new therapeutic for insomnia because it is amenable to chemical modification to generate druggable analogs and it has no intellectual property roadblocks. We will achieve our goal through the accomplishment of two Specific Aims. Aim 1 Lead modification. Explore the structure-activity relationship (SAR) of ~200 new synthetic analogs derived from ML297 and identify the top 10 modified leads with increased potency and selectivity. Aim 2. Therapeutic lead discovery through in vitro and in vivo PK studies. We will determine the in vivo PK profiles of the top 3 new leads and test the best lead in a pilot sleep study in rats using EEG/EMG. Success in the Phase I project will demonstrate feasibility of discovering a druggable GIRK1/2 channel direct activator. In a Phase II project, we will focus on lead optimization to discover a safe therapeutic candidate with desirable PK/PD profile for the IND-enabling studies, and ultimately for the treatment of chronic insomnia.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	AFASCI INC	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	000	2	2/1/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $249,909 )
2019	2019	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	003	2	9/16/2019	SUPPLEMENT FOR EXPANSION	$0
2019	2019	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	001	2	7/15/2019	SUPPLEMENT FOR EXPANSION	$100,389
2019	2019	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	002	2	8/16/2019	SUPPLEMENT FOR EXPANSION	$0
2019	2019	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	004	2	9/17/2019	NON-COMPETING CONTINUATION	$0
2019	2019	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	National Center on Sleep Disorders Research	000	2	7/11/2019	NON-COMPETING CONTINUATION	$149,520
														Subtotal = $249,909

Issue Date FY: 2018 ( Subtotal = $149,520 )
2018	2018	AFASCI, INC.	2633 MARTINEZ DR	BURLINGAME	CA	94010	SAN MATEO	USA	Lung Diseases Research	000	1	9/17/2018	NEW	$149,520
														Subtotal = $149,520

Grand Total All Awards = $399,429

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic

Award Number: R43HL142315

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/17/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer